No Alzheimer's benefits in supplements - NIH panel
This article was originally published in The Tan Sheet
Executive Summary
Data do not support the association of dietary supplement intake and drug regimens with reduced risk of Alzheimer's disease, says a National Institutes of Health panel. Following a state-of-the-science conference April 26-28 in Bethesda, Md., the panel said in a 1statement that longer chain omega-3 fatty acids demonstrate some reduced risk of cognitive decline in longitudinal studies and "may provide new insight into the prevention or delay of cognitive decline or Alzheimer's." Other nutritional interventions, including folate, beta-carotene and vitamins B, E and C, show no consistent cognitive benefits, the panel said. Products touting support for brain and memory health products are a growing supplement segment (2"The Tan Sheet" Dec. 21, 2009)
You may also be interested in...
Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply
Ovos Natural Health plans a 2010 U.S. launch of its Vivimind cognitive health supplement, contingent upon FDA's go-ahead
Warning Letter Roundup & Recap – January 2023
The US Food and Drug Administration published three device-related warning letters in January – two that went to divisions of endoscope vendor Olympus, and one to a Maryland vision treatment firm.
US FDA Urged To Improve Messaging To Professional Societies On Accelerated Approval Withdrawals
Lengthy withdrawal process creates an opening for the FDA to better convey its concerns about a medicine’s benefit-risk profile in a way that impacts prescribing guidelines, Johns Hopkins’ Joshua Sharfstein says; CDER’s Jacqueline Corrigan-Curay says new expedited withdrawal procedures under omnibus law appear more ‘streamlined’ than those followed for Makena.